DK1857555T3 - Fremgangsmåde til fremstilling af et celle- og/eller vævs- og/eller sygdomsfase-specifikt lægemiddel - Google Patents
Fremgangsmåde til fremstilling af et celle- og/eller vævs- og/eller sygdomsfase-specifikt lægemiddelInfo
- Publication number
- DK1857555T3 DK1857555T3 DK07013576T DK07013576T DK1857555T3 DK 1857555 T3 DK1857555 T3 DK 1857555T3 DK 07013576 T DK07013576 T DK 07013576T DK 07013576 T DK07013576 T DK 07013576T DK 1857555 T3 DK1857555 T3 DK 1857555T3
- Authority
- DK
- Denmark
- Prior art keywords
- cell
- tissue
- rna
- dnazyme
- target cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10346487A DE10346487A1 (de) | 2003-10-02 | 2003-10-02 | Verfahren zur Herstellung eines Zell- und/oder Gewebe- und/oder Krankheitsphasen-spezifischen Arzneimittels |
| PCT/DE2004/002197 WO2005033314A2 (de) | 2003-10-02 | 2004-10-01 | Verfahren zur herstellung eines zell- und/oder gewebe- und/oder krankheitsphasen-spezifischen arzneimittels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1857555T3 true DK1857555T3 (da) | 2009-05-04 |
Family
ID=34399325
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07013576T DK1857555T3 (da) | 2003-10-02 | 2004-10-01 | Fremgangsmåde til fremstilling af et celle- og/eller vævs- og/eller sygdomsfase-specifikt lægemiddel |
| DK04802618T DK1670919T3 (da) | 2003-10-02 | 2004-10-01 | Fremgangsmåde til fremstilling af et cellespecifikt og/eller vævsspecifikt og/eller sygdomsfasespecifikt lægemiddel |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK04802618T DK1670919T3 (da) | 2003-10-02 | 2004-10-01 | Fremgangsmåde til fremstilling af et cellespecifikt og/eller vævsspecifikt og/eller sygdomsfasespecifikt lægemiddel |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8119789B2 (da) |
| EP (2) | EP1670919B1 (da) |
| JP (2) | JP5013870B2 (da) |
| KR (1) | KR101121818B1 (da) |
| AT (2) | ATE419364T1 (da) |
| CA (2) | CA2541240C (da) |
| CY (1) | CY1108161T1 (da) |
| DE (3) | DE10346487A1 (da) |
| DK (2) | DK1857555T3 (da) |
| ES (2) | ES2320706T3 (da) |
| PL (2) | PL1857555T3 (da) |
| PT (2) | PT1857555E (da) |
| SI (1) | SI1670919T1 (da) |
| WO (1) | WO2005033314A2 (da) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI322690B (en) | 2006-05-11 | 2010-04-01 | Flysun Dev Co Ltd | Short interference ribonucleic acids for treating allergic dieases |
| EP2408915A2 (en) * | 2009-03-19 | 2012-01-25 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| WO2010110314A1 (ja) * | 2009-03-27 | 2010-09-30 | 協和発酵キリン株式会社 | 核酸を含有する肺高血圧症治療剤 |
| DE102010007562A1 (de) | 2010-02-10 | 2011-08-11 | sterna biologicals GmbH & Co KG, 35043 | Dermatologische, pharmazeutische Zusammensetzung geeignet für Oligonukleotide |
| DE102010056610A1 (de) * | 2010-12-31 | 2012-07-05 | Volker A. Erdmann | Pharmazeutische Zusammensetzung enthaltend L-DNA |
| DE102011109868A1 (de) * | 2011-08-10 | 2013-02-14 | STERNA BIOLOGICALS GmbH & Co. KG. | Multiple Emulsion |
| EP2708898A1 (de) | 2012-09-14 | 2014-03-19 | Sterna Biologicals GmbH & Co. Kg | Verfahren zur Diagnose eines molekularen Phänotyps eines an einer mit chronischen Entzündungen einhergehenden Erkrankung leidenden Patienten |
| PT3093022T (pt) * | 2015-05-15 | 2019-11-11 | Sterna Biologicals Gmbh & Co Kg | Inibidores gata-3 para utilização no tratamento de asma desencadeada por th2 |
| EP3211081A1 (en) | 2016-02-26 | 2017-08-30 | Secarna Pharmaceuticals GmbH & Co. KG | Novel approach for treating inflammatory disorders |
| US10647987B2 (en) | 2016-02-26 | 2020-05-12 | Secama Pharmaceuticals GmbH & Co KG | Approach for treating inflammatory disorders |
| EP3463388A4 (en) | 2016-05-24 | 2020-01-01 | Emory University | PARTICLES CONJUGATED TO RNA-DIVIDING NUCLEOBASE POLYMERS AND USES THEREOF IN THE MANAGEMENT OF INFLAMMATORY DISORDERS |
| EP3501607A1 (de) | 2017-12-22 | 2019-06-26 | Sterna Biologicals GmbH & Co. KG | Zusammensetzung zur behandlung eines an einer mit chronischen entzündungen einhergehenden atemwegserkrankung leidenden patienten sowie herstellungsverfahren und verwendung der zusammensetzung |
| PT3514235T (pt) * | 2018-01-18 | 2024-02-12 | Sterna Biologicals Gmbh | Composição para o tratamento de um doente que sofre de colite ulcerosa, assim como utilização da composição como medicamento |
| US20210022324A1 (en) * | 2018-03-05 | 2021-01-28 | Dr. Reddy's Institute Of Life Sciences | Embryonic zebrafish models using dnazyme mediated knockdown |
| EP3603617A1 (de) | 2018-07-30 | 2020-02-05 | Sterna Biologicals GmbH & Co. KG | Aerosolerzeugungseinrichtung zur inhalativen verabreichung einer antisense-molekül-haltigen zusammensetzung |
| EP3805242A1 (en) | 2019-10-07 | 2021-04-14 | Sterna Biologicals GmbH & Co. KG | Method for the production of a catalytically active dna molecule having improved activity and its use in a method of treating asthma |
| US11976282B2 (en) | 2020-06-23 | 2024-05-07 | Qatar University | GATA3 inhibitors for the promotion of subcutaneous fat deposition |
| AU2021411103A1 (en) * | 2020-12-28 | 2023-07-13 | 1E Therapeutics, Ltd. | P21 mrna target areas for silencing |
| EP4267742A2 (en) | 2020-12-28 | 2023-11-01 | 1E Therapeutics, Ltd. | P21 mrna targeting dnazymes |
| WO2023052422A1 (en) | 2021-09-30 | 2023-04-06 | Sterna Biologicals Gmbh | Dnazyme hydrogel formulations |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999050452A1 (en) * | 1998-03-27 | 1999-10-07 | Johnson & Johnson Research Pty. Limited | Catalytic nucleic acid-based diagnostic methods |
| KR20010072475A (ko) * | 1998-08-13 | 2001-07-31 | 추후제출 | 재발협착증을 치료하기 위한 ｄｎａ자임 및 치료 방법 |
| AUPP810399A0 (en) * | 1999-01-11 | 1999-02-04 | Unisearch Limited | Catalytic molecules |
| IL145034A0 (en) * | 1999-03-05 | 2002-06-30 | Epigenesis Pharmaceuticals Inc | Method for validating/invalidating target(s) and pathways |
| AUPQ201499A0 (en) * | 1999-08-04 | 1999-08-26 | Unisearch Limited | Treatment of inflammatory and malignant diseases |
| WO2002068637A2 (en) * | 2000-10-20 | 2002-09-06 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid-based treatment of diseases or conditions related to west nile virus infection |
| US20030148971A1 (en) * | 2002-02-04 | 2003-08-07 | Handel Malcolm Lovell | Treatment of inflammatory and malignant diseases |
-
2003
- 2003-10-02 DE DE10346487A patent/DE10346487A1/de not_active Withdrawn
-
2004
- 2004-10-01 DE DE502004006791T patent/DE502004006791D1/de active Active
- 2004-10-01 SI SI200430734T patent/SI1670919T1/sl unknown
- 2004-10-01 PL PL07013576T patent/PL1857555T3/pl unknown
- 2004-10-01 AT AT07013576T patent/ATE419364T1/de active
- 2004-10-01 DK DK07013576T patent/DK1857555T3/da active
- 2004-10-01 ES ES07013576T patent/ES2320706T3/es active Active
- 2004-10-01 PL PL04802618T patent/PL1670919T3/pl unknown
- 2004-10-01 DE DE502004008802T patent/DE502004008802D1/de active Active
- 2004-10-01 EP EP04802618A patent/EP1670919B1/de active Active
- 2004-10-01 JP JP2006529624A patent/JP5013870B2/ja active Active
- 2004-10-01 KR KR1020067008072A patent/KR101121818B1/ko active IP Right Grant
- 2004-10-01 US US10/574,560 patent/US8119789B2/en active Active
- 2004-10-01 AT AT04802618T patent/ATE391788T1/de active
- 2004-10-01 EP EP07013576A patent/EP1857555B1/de active Active
- 2004-10-01 WO PCT/DE2004/002197 patent/WO2005033314A2/de active IP Right Grant
- 2004-10-01 ES ES04802618T patent/ES2304633T3/es active Active
- 2004-10-01 PT PT07013576T patent/PT1857555E/pt unknown
- 2004-10-01 CA CA2541240A patent/CA2541240C/en active Active
- 2004-10-01 PT PT04802618T patent/PT1670919E/pt unknown
- 2004-10-01 CA CA2776997A patent/CA2776997C/en active Active
- 2004-10-01 DK DK04802618T patent/DK1670919T3/da active
-
2008
- 2008-06-27 CY CY20081100675T patent/CY1108161T1/el unknown
-
2011
- 2011-01-14 JP JP2011005485A patent/JP5291129B2/ja active Active
- 2011-03-01 US US13/037,411 patent/US8247544B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1108161T1 (el) | Μεθοδος για την παραγωγη φαρμακευτικου μεσου με κυτταρικη ειδικοτητα και/ή ιστικη ειδικοτητα και/ή ειδικοτητα φασης νοσου | |
| US20200202981A1 (en) | Methods for designing guide sequences for guided nucleases | |
| Fang et al. | MicroRNAs regulate bone development and regeneration | |
| Lister et al. | Turning over DNA methylation in the mind | |
| Beemelmanns et al. | Synthesis of the rosette-inducing factor RIF-1 and analogs | |
| Walker et al. | Photoactivation of mutant isocitrate dehydrogenase 2 reveals rapid cancer-associated metabolic and epigenetic changes | |
| Orapiriyakul et al. | Nanovibrational stimulation of mesenchymal stem cells induces therapeutic reactive oxygen species and inflammation for three-dimensional bone tissue engineering | |
| Li et al. | Upregulation of lncRNA VDR/CASC15 induced by facilitates cardiac hypertrophy through modulating miR-432-5p/TLR4 axis | |
| TR201909609T4 (tr) | Modifiye edilmiş nükleosidleri içeren rna ve kullanım yöntemleri. | |
| Sada et al. | Near-IR laser-triggered target cell collection using a carbon nanotube-based cell-cultured substrate | |
| Zhang et al. | Multiplexed photoactivation of mRNA with single-Cell resolution | |
| Davis et al. | The polyadenylation code: a unified model for the regulation of mRNA alternative poly adenylation | |
| Siwkowski et al. | Analysis of hairpin ribozyme base mutations in loops 2 and 4 and their effects on cis-cleavage in vitro | |
| Zhu et al. | Epigenetic regulation of organ regeneration in zebrafish | |
| Kour et al. | Interplay between circular RNA, microRNA, and human diseases | |
| Shi et al. | Harnessing PUF-Based Reporters for Noninvasive Imaging of the MicroRNA Dynamics in Differentiation | |
| Tan et al. | Non-coding RNAs in the regulation of hippocampal neurogenesis and potential treatment targets for related disorders | |
| Gjaltema et al. | KRAB-induced heterochromatin effectively silences PLOD2 gene expression in somatic cells and is resilient to TGFβ1 activation | |
| Wegrzyn et al. | Genome editing: insights from chemical biology to support safe and transformative therapeutic applications | |
| Farber et al. | Reprogramming of non-myocytes into cardiomyocyte-like cells: challenges and opportunities | |
| Kim et al. | 17β-Estradiol regulates miR-9-5p and miR-9-3p stability and function in the aged female rat brain | |
| Crey-Desbiolles et al. | 3-Nitro-3-deaza-2 ‘-deoxyadenosine as a Versatile Photocleavable 2 ‘-Deoxyadenosine Mimic | |
| CN108148836A (zh) | 一种肝再生相关长链非编码rna及其抑制剂和应用 | |
| Rossi et al. | Discovery of small peptides derived from embryonic lethal abnormal vision proteins structure showing RNA-stabilizing properties | |
| Bérenger-Currias et al. | Pluripotent Stem Cells in Disease Modeling and Drug Discovery for Myotonic Dystrophy Type 1 |